Real World Hospital Costs Associated With Nab-Paclitaxel Plus Gemcitabine (Nab-P Plus G) And Folfirinox (Ffx) As First Line (1 L) Treatment (Tx) For Metastatic Pancreatic Adenocarcinoma (Mpac).
JOURNAL OF CLINICAL ONCOLOGY(2016)
摘要
e15741 Background: In independent phase III trials, both nab-P+G and FFX demonstrated superiority over G as 1L MPAC tx. Limited data exist on real world effectiveness and costs of nab-P+G v FFX. This study compared median time to tx discontinuation (TTD) and costs between the two cohorts. Methods: A retrospective study was conducted with MedAssets’ de-identified US hospital data. Patients (pts) ≥ 18 yo diagnosed with MPAC between 04/13 and 02/15, completing ≥ 1 cycle of nab-P+G or FFX as 1L, and with ≥ 6 months of data were included. Primary endpoints were median TTD and total costs. Supportive care use and costs were also examined. Between group comparisons used Kaplan-Meier (TTD) and ANOVA (costs). Multivariable general linear regression with gamma distributions were used for costs. Results: A total of 89 pts received nab-P+G, while 61 received FFX. nab-P+G pts were older (age ≥ 70: 31.5% v 11.5%; p < 0.05) compared to FFX, though Charlson Comorbidity Indices were similar (nab-P+G = 8.8, FFX = 9.0). More nab-P+G pts were treated in teaching (56% v 49%) and < 200 bed facilities (27% v 21%), but these differences were not significant. Median TTD did not differ significantly between nab-P+G (120 days) and FFX (98 days; p = 0.77). Median costs per month of tx were lower in nab-P+G pts ($12,192 v $18,743, p < 0.01). More FFX pts used GCSF (66.7% v 22.5%, p < 0.01), while more nab-P+G pts used blood products (BP) (30.0 v 10.4%, p < 0.05). Monthly GCSF and antiemetic costs were lower in nab-P+G pts ($1,584 v $4,793, p < 0.05; $595 v $1,351, p < 0.05). Multivariable analysis confirmed higher total costs (IRR = 1.4, p < 0.01), GCSF costs (IRR = 2.5, p < 0.05) and antiemetic costs (IRR = 6.4, p < 0.01) in FFX pts. No significant differences were seen in BP costs between cohorts. Monthly inpatient costs were lower for nab-P+G ($510 v $3,503, p < 0.01) but not significant (p = 0.18) when controlling for baseline variables. Conclusions: While median TTD was similar between nab-P+G and FFX cohorts, pts treated with FFX had higher total costs driven in part by use of GCSF, antiemetics, and inpatient visits.
更多查看译文
关键词
metastatic pancreatic adenocarcinoma,real world hospital costs,hospital costs,nab-paclitaxel
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要